)
)
)
Alzheon
ALZ-801 is an oral candidate for Alzheimer's Disease with a strong safety profile. Results of the first placebo-controlled Phase 3 trial completed in 2024 overall favored ALZ-801. Alzheon is planning a second Phase 3 trial to confirm the highly significant (p<0.001) effect in MCI APOE4/4 patients, and expand the trial to APOE4 heterozygous patients. Alzheon recently met with the FDA and the PMDA and is now seeking partnership to further develop ALZ-801, pursue regulatory approval and commercialize.
Address
FraminghamMA
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)